ODT

Odonate Therapeutics, Inc. [ODT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ODT Stock Summary

In the News

ODT Financial details

Company Rating
-
Market Cap
0
Income
-102.07M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
137
Optionable
No
Shortable
Yes
Earnings
10 Nov 2021
P/E
-0.29
Forward P/E
-
PEG
0.1
P/S
-
P/B
0.27
P/C
-
P/FCF
-
Quick Ratio
5.81
Current Ratio
5.91
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.83
EPS next Y
-
EPS next Q
-
EPS this Y
-4.94%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-36.21%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-75%
ROE
-85%
ROC
-0.9%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.1107-1.2
52W High
+12%
52W Low
+12%
RSI
-
Rel Volume
0.75
Avg Volume
959.82K
Volume
716.44K
Perf Week
0%
Perf Month
0%
Perf Quarter
-
Perf Half Y
-13.18%
-
-
-
-
Beta
0.453027
-
-
Volatility
0%, 0%
Prev Close
0%
Price
1.12
Change
0.84%

Something similar

Top by Market Cap
BRK-A
0YXG.L
AAPL
VFINX
VOO
Same Sector
BLISSGVS.NS
ZYME
600380.SS
VRTX
002370.SZ
Check Those
BBU-UN.TO
ERLFF
034020.KS
AOT-R.BK
SDOS.ST
Similar Market Cap
SPCE
1101.HK
9912.TW
002686.SZ
SBB-D.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 959.82K
  • Employee 137
  • CEO Mr. Kevin Tang
  • Headquarters San Diego,CALIFORNIA,US
  • IPO Date 2017-12-07
  • Website https://www.odonate.com

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.